Also known as Mounjaro, Zepbound, and tirzepatida.
chemXplore tracks 1 project producing tirzepatide, of which one is active.
Of the active ones, 1 new construction.
Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.
EBGLYSS shows durable control, less maintenance dosing and reduced topical use; TOGETHER‑PsO biomarker data assess Taltz+Zepbound vs Taltz; Olumiant pediatric alopecia areata results also included.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.
Ro telehealth real-world data: mean 4.1% weight loss at three months; 40.7% reached ≥5% loss; obesity (BMI≥30) prevalence fell 21.6 percentage points; N=194.
fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.
Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.
Real-world claims analysis found escalating from semaglutide 1 mg to 2 mg tied to a 6% lower risk of major adverse cardiovascular events than switching to tirzepatide.
An indirect, covariate‑adjusted comparison of SURMOUNT‑1 and STEP UP data shows larger mean and categorical weight‑loss benefits with tirzepatide 10 mg and 15 mg at 72 weeks.
